A5011423603- Breast Cancer Treatment Studies
- Cutaneous Melanoma Detection and Management
- Estrogen and related hormone effects
- BRCA gene mutations in cancer
- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- Statistical Methods in Clinical Trials
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Ovarian cancer diagnosis and treatment
- Cancer Cells and Metastasis
- Breast Implant and Reconstruction
- Head and Neck Cancer Studies
- Brain Metastases and Treatment
- Testicular diseases and treatments
- Global Cancer Incidence and Screening
- DNA Repair Mechanisms
- Epigenetics and DNA Methylation
- Cardiac, Anesthesia and Surgical Outcomes
- PARP inhibition in cancer therapy
- Childhood Cancer Survivors' Quality of Life
Medizinische Hochschule Brandenburg Theodor Fontane
2019-2025
The Netherlands Cancer Institute
2015-2023
Oncode Institute
2015-2023
Military University of Technology in Warsaw
2021
Dutch Cancer Society
2017-2019
University Medical Center Utrecht
2016-2018
Netherlands Comprehensive Cancer Organisation
2017-2018
University of Twente
2017-2018
Radboud University Nijmegen
2016-2017
Radboud University Medical Center
2017
Background: Although BRCA1-deficient tumors are extremely sensitive to DNA-damaging drugs and poly(ADP-ribose) polymerase (PARP) inhibitors, recurrences do occur and, consequently, resistance therapy remains a serious clinical problem. To study the underlying mechanisms, we induced in patient-derived xenograft (PDX) models of BRCA1-mutated BRCA1-methylated triple-negative breast cancer. Methods: A cohort 75 mice carrying PDX was treated with cisplatin, melphalan, nimustine, or olaparib,...
Triple-negative breast cancer (TNBC) is considered aggressive, and therefore, virtually all young patients with TNBC receive (neo)adjuvant chemotherapy. Increased stromal tumor-infiltrating lymphocytes (sTILs) have been associated a favorable prognosis in TNBC. However, whether this association holds for who are node-negative (N0), (< 40 years), chemotherapy-naïve, thus can be used chemotherapy de-escalation strategies, unknown.We selected N0 diagnosed between 1989 2000 from Dutch...
ObjectivesIn Germany the coronavirus disease 2019 (COVID-19) pandemic situation is unique among large European countries in that incidence and case fatality rate are distinctly lower. We describe clinical course examine factors associated with outcomes patients hospitalized COVID-19 Germany.MethodsIn this retrospective cohort study we included admitted to a national network of German hospitals between February 12 June 12, 2020. examined demographic characteristics, comorbidities...
The host’s immune system plays a pivotal role in many tumor types, including squamous cell carcinomas (SCCs). We aim to identify immunological prognosticators for lymph node metastases (LNM) and disease specific survival (DSS) penile carcinoma (SCC). For this retrospective observational cohort study, SCC patients (n=213) treated the Netherlands Cancer Institute, were selected if sufficient formalin-fixed, paraffin-embedded material was available. Analysis included previously described...
<h3>Importance</h3> Previous studies of breast cancer risk after in vitro fertilization (IVF) treatment were inconclusive due to limited follow-up. <h3>Objective</h3> To assess long-term ovarian stimulation for IVF. <h3>Design, Setting, and Participants</h3> Historical cohort (OMEGA study) with complete follow-up through December 2013 96% the cohort. The included 19 158 women who started IVF between 1983 1995 (IVF group) 5950 starting other fertility treatments 1980 (non-IVF from all 12...
Purpose Testicular cancer (TC) treatment increases risk of subsequent malignant neoplasms (SMNs). It is unknown whether changes in TC over time have affected SMN risk. Methods Solid was evaluated a multicenter cohort comprising 5,848 1-year survivors treated for before age 50 years between 1976 and 2007. incidence compared with the general population. Treatment-specific risks were assessed using multivariable regression case-cohort design. Results After median follow-up 14.1 years, 350 solid...
Neoadjuvant chemotherapy is standard of care in human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC), irrespective the hormone status. Trastuzumab-emtansine (T-DM1), antibody-drug conjugate, highly effective HER2+ EBC; however, no survival data are available for de-escalated conjugate-based neoadjuvant therapy without conventional chemotherapy.In WSG-ADAPT-TP (ClinicalTrials.gov identifier: NCT01779206) phase II trial, 375 centrally reviewed patients with...
Abstract Ductal carcinoma in situ (DCIS) of the female breast is treated with surgery possibly followed by radiotherapy (RT) and/or adjuvant hormonal therapy despite their known long-term side effects. Since not every DCIS will progress into an invasive cancer (IBC), disease progression and de-escalation treatment important topic current research. During 2007–2020, 3905 individuals a diagnosis were reported to registry Brandenburg Berlin. We selected 3424 women who cancer-free prior without...
Abstract Background New data show that not only HER2-overexpressing breast cancer (BC) tumors but also HER2-low tumors, classically considered as HER2-negative, respond to HER2-targeting antibody–drug-conjugates. Our objective was analyze the prevalence of BC in a pooled analysis contemporary early trials and evaluate its role prognostic factor terms survival comparison HER2-zero BC. Methods We evaluated 5598 patients with locally HR + /HER2- from screening cohort WSG-ADAPT-HR /HER2-, 2592...
Ultrasound-guided breast-conserving surgery (USS) results in a significant reduction both margin involvement and excision volumes (COBALT trial). The aim of the present study was to determine whether USS also leads improvements cosmetic outcome patient satisfaction when compared with standard palpation-guided (PGS). A total 134 patients T1–T2 invasive breast cancer were included COBALT trial (NTR2579) randomized either (65 patients) or PGS (69 patients). Cosmetic outcomes assessed by...
Pseudomyxoma peritonei (PMP) is a rare disease, most commonly of appendiceal origin. Treatment consists cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). The aim this study was to identify prognostic factors for recurrence survival.This an observational using prospectively designed database containing consecutive patients with PMP originating from the appendix, undergoing CRS-HIPEC at tertiary referral centre between 1996 2015. Histopathological slides were...
Abstract Purpose: BRCA1-deficient breast cancers carry a specific DNA copy-number signature (“BRCA1-like”) and are hypersensitive to double-strand break (DSB) inducing compounds. Here, we explored whether (i) EZH2 is overexpressed in human tumors might predict sensitivity DSB-inducing drugs; (ii) inhibition potentiates cisplatin efficacy Brca1-deficient murine mammary tumors. Experimental Design: expression was analyzed 497 using IHC or RNA sequencing. We classified 370 by profiles as...
Abstract The prognostic value of cytonuclear grade in ductal carcinoma situ (DCIS) is debated, partly due to high interobserver variability and the use multiple guidelines. aim this study was evaluate agreement grading DCIS between Dutch, British, American pathologists. Haematoxylin eosin‐stained slides 425 women with primary were independently reviewed by nine breast pathologists based Netherlands, UK, USA. Chance‐corrected kappa ( κ ma ) for association calculated on a generalised linear...
Introduction Cosmetic results and quality of life (QoL) are increasingly important in the treatment breast cancer. This study was designed to determine relationship between QoL both subjectively objectively measured cosmetic outcomes breast‐conserving therapy (BCT), its course over time. Methods A total 128 cancer patients who underwent BCT as part a prospective randomized controlled trial were included. using EORTC QLQ‐C30 QLQ‐BR23 at baseline, 3, 6, 12, 36 months. outcome determined by...
Background and Objectives To identify breast‐specific factors the role of tumor, treatment, patient‐related items in influencing patient opinion on cosmesis satisfaction after breast‐conserving therapy (BCT). Methods Data from randomized COBALT study was used. At 3, 12, 36 months, 128 patients with T1‐T2 breast cancer completed a questionnaire overall cosmetic outcome satisfaction, using 4‐point Likert scale. Results There strong positive correlation between factors, outcome,and at all...